Mitotic drug targets
- PMID: 20518069
- DOI: 10.1002/jcb.22721
Mitotic drug targets
Abstract
Mitosis is the key event of the cell cycle during which the sister chromatids are segregated onto two daughter cells. It is well established that abrogation of the normal mitotic progression is a highly efficient concept for anti-cancer treatment. In fact, various drugs that target microtubules and thus interfere with the function of the mitotic spindle are in clinical use for the treatment of various human malignancies for many years. However, since microtubule inhibitors not only target proliferating cells severe side effects limit their use. Therefore, the identification of novel mitotic drug targets other than microtubules have gained recently much attention. This review will summarize the latest developments on the identification and clinical evaluation of novel mitotic drug targets and will introduce novel concepts for chemotherapy that are based on recent progress in our understanding how mitotic progression is regulated and how anti-mitotic drugs induce tumor cell death.
© 2010 Wiley-Liss, Inc.
Similar articles
-
Mitotic drug targets and the development of novel anti-mitotic anticancer drugs.Drug Resist Updat. 2007 Aug-Oct;10(4-5):162-81. doi: 10.1016/j.drup.2007.06.003. Epub 2007 Jul 31. Drug Resist Updat. 2007. PMID: 17669681 Review.
-
How do anti-mitotic drugs kill cancer cells?J Cell Sci. 2009 Aug 1;122(Pt 15):2579-85. doi: 10.1242/jcs.039719. J Cell Sci. 2009. PMID: 19625502 Review.
-
Emerging mitotic inhibitors for non-small cell carcinoma.Expert Opin Emerg Drugs. 2013 Mar;18(1):97-107. doi: 10.1517/14728214.2013.777426. Expert Opin Emerg Drugs. 2013. PMID: 23448156 Review.
-
Targeting mitosis for anti-cancer therapy.BioDrugs. 2007;21(4):225-33. doi: 10.2165/00063030-200721040-00003. BioDrugs. 2007. PMID: 17628120 Review.
-
Inhibitors targeting mitosis: tales of how great drugs against a promising target were brought down by a flawed rationale.Clin Cancer Res. 2012 Jan 1;18(1):51-63. doi: 10.1158/1078-0432.CCR-11-0999. Clin Cancer Res. 2012. PMID: 22215906 Review.
Cited by
-
KIF18B promotes tumor progression through activating the Wnt/β-catenin pathway in cervical cancer.Onco Targets Ther. 2018 Mar 28;11:1707-1720. doi: 10.2147/OTT.S157440. eCollection 2018. Onco Targets Ther. 2018. PMID: 29636620 Free PMC article.
-
Selective Tumor Targeting of Desacetyl Vinblastine Hydrazide and Tubulysin B via Conjugation to a Cholecystokinin 2 Receptor (CCK2R) Ligand.Mol Pharm. 2015 Jul 6;12(7):2477-83. doi: 10.1021/acs.molpharmaceut.5b00218. Epub 2015 Jun 16. Mol Pharm. 2015. PMID: 26043355 Free PMC article.
-
Defective cell cycle checkpoints as targets for anti-cancer therapies.Front Pharmacol. 2012 Feb 2;3:9. doi: 10.3389/fphar.2012.00009. eCollection 2012. Front Pharmacol. 2012. PMID: 22347187 Free PMC article.
-
Up-regulation of pro-apoptotic protein Bim and down-regulation of anti-apoptotic protein Mcl-1 cooperatively mediate enhanced tumor cell death induced by the combination of ERK kinase (MEK) inhibitor and microtubule inhibitor.J Biol Chem. 2012 Mar 23;287(13):10289-10300. doi: 10.1074/jbc.M111.319426. Epub 2012 Jan 23. J Biol Chem. 2012. PMID: 22270368 Free PMC article.
-
Microtubule Targeting Agents in Disease: Classic Drugs, Novel Roles.Cancers (Basel). 2021 Nov 12;13(22):5650. doi: 10.3390/cancers13225650. Cancers (Basel). 2021. PMID: 34830812 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources